Prognostic Significance of Serum Tumor Markers in Patients with
Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy

J 2016

Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Martin SVATON; Ondrej SOREJS et. al.

Basic information

Original name

Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy

Authors

FIALA, Ondrej (203 Czech Republic); Milos PESEK (203 Czech Republic); Jindrich FINEK (203 Czech Republic); Martin SVATON (203 Czech Republic); Ondrej SOREJS (203 Czech Republic); Zbyněk BORTLÍČEK (203 Czech Republic, guarantor, belonging to the institution); Radek KUCERA (203 Czech Republic) and Ondrej TOPOLCAN (203 Czech Republic)

Edition

Anticancer Research, Athens, The International Institute of Anticancer Research, 2016, 0250-7005

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Greece

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 1.937

RIV identification code

RIV/00216224:14110/16:00089326

Organization unit

Faculty of Medicine

UT WoS

000367450000066

Keywords in English

Lung cancer; NSCLC; tumor marker; prognosis; pemetrexed

Abstract

In the original language

Background: Tumor biomarkers represent effective tools for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Patients and Methods: In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. Comparison of progression-free (PFS) and overall survival (OS) according to the level of assessed tumor markers was performed using the log-rank test. Results: We recorded significantly shorter OS for patients with high pretreatment levels of CYFRA 21-1 (10.3 vs. 23.4 months; p<0.001), NSE (1.6 vs. 13.5 months; p=0.003) and TK (11.3 vs. 23.4 months; p=0.003). Conclusion: CYFRA 21-1, NSE and TK are feasible biomarkers for estimation of a patient's overall prognosis, however, none of the measured serum tumor markers were able to predict the efficacy of pemetrexed-based chemotherapy.

Cite

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Martin SVATON; Ondrej SOREJS; Zbyněk BORTLÍČEK; Radek KUCERA and Ondrej TOPOLCAN. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. Anticancer Research. Athens: The International Institute of Anticancer Research, 2016, vol. 36, No 1, p. 461-466. ISSN 0250-7005.

@article{1333785,
   author = {Fiala, Ondrej and Pesek, Milos and Finek, Jindrich and Svaton, Martin and Sorejs, Ondrej and Bortlíček, Zbyněk and Kucera, Radek and Topolcan, Ondrej},
   article_location = {Athens},
   article_number = {1},
   keywords = {Lung cancer; NSCLC; tumor marker; prognosis; pemetrexed},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy},
   volume = {36},
   year = {2016}
}

TY  - JOUR
ID  - 1333785
AU  - Fiala, Ondrej - Pesek, Milos - Finek, Jindrich - Svaton, Martin - Sorejs, Ondrej - Bortlíček, Zbyněk - Kucera, Radek - Topolcan, Ondrej
PY  - 2016
TI  - Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy
JF  - Anticancer Research
VL  - 36
IS  - 1
SP  - 461-466
EP  - 461-466
PB  - The International Institute of Anticancer Research
SN  - 02507005
KW  - Lung cancer
KW  - NSCLC
KW  - tumor marker
KW  - prognosis
KW  - pemetrexed
N2  - Background: Tumor biomarkers represent effective tools for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Patients and Methods: In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. Comparison of progression-free (PFS) and overall survival (OS) according to the level of assessed tumor markers was performed using the log-rank test. Results: We recorded significantly shorter OS for patients with high pretreatment levels of CYFRA 21-1 (10.3 vs. 23.4 months; p<0.001), NSE (1.6 vs. 13.5 months; p=0.003) and TK (11.3 vs. 23.4 months; p=0.003). Conclusion: CYFRA 21-1, NSE and TK are feasible biomarkers for estimation of a patient's overall prognosis, however, none of the measured serum tumor markers were able to predict the efficacy of pemetrexed-based chemotherapy.
ER  -

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Martin SVATON; Ondrej SOREJS; Zbyněk BORTLÍČEK; Radek KUCERA and Ondrej TOPOLCAN. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. \textit{Anticancer Research}. Athens: The International Institute of Anticancer Research, 2016, vol.~36, No~1, p.~461-466. ISSN~0250-7005.

Přehled o publikaci